44B988F8-8B4B-4B7C-B91E-99C513F7E753
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 14.060446780551905
- age_years
- 57
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.434
- WNT_BETA_CATENIN_SIGNALING+0.400
- NOTCH_SIGNALING+0.396
- CHOLESTEROL_HOMEOSTASIS+0.387
- MYC_TARGETS_V2+0.378
- DNA_REPAIR+0.365
- OXIDATIVE_PHOSPHORYLATION+0.351
- ADIPOGENESIS+0.291
- INTERFERON_ALPHA_RESPONSE+0.286
- HEDGEHOG_SIGNALING+0.259
Top 10 suppressed
- SPERMATOGENESIS-0.299
- KRAS_SIGNALING_DN-0.226
- PANCREAS_BETA_CELLS-0.217
- UV_RESPONSE_DN-0.177
- ANGIOGENESIS-0.166
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.141
- HYPOXIA-0.139
- ESTROGEN_RESPONSE_LATE-0.092
- MYOGENESIS-0.090
- TNFA_SIGNALING_VIA_NFKB-0.084
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 64E6EE5B-414F-4D8C-BA90-5A74B4FF5904 | — | — | 0.858 |
| 2 | D837BDD1-8786-4548-8D5F-8506AECF2006 | — | — | 0.852 |
| 3 | B13E4D9F-672E-4A9A-8745-0AE5308678C1 | — | — | 0.850 |
| 4 | 37E6F027-C405-4671-80BD-CC40684DE803 | — | — | 0.845 |
| 5 | 46AD8592-A823-48DA-AB51-3CEC34F53E04 | — | — | 0.844 |
| 6 | A7D9F5B1-D8C2-440F-A0B7-8B5641C2DA66 | — | — | 0.842 |
| 7 | AFCB278F-0EFB-4999-8D2C-C72B89A8403E | — | — | 0.836 |
| 8 | 913D6292-6507-4F86-A120-137CEACE5C9F | — | — | 0.833 |
| 9 | 85EE23A9-B5E4-49F7-A504-CEF2EB4E4E7E | — | — | 0.829 |
| 10 | 0915FD2C-0C30-4437-83BA-DFBDF3CDBC61 | — | — | 0.829 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 38 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.434 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.400 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.396 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.387 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.378 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.365 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.351 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.291 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.286 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.259 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.256 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.226 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.212 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.195 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.194 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.185 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.182 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.174 | Idelalisib | — uncovered |
| COMPLEMENT | 0.163 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.155 | Inavolisib | — uncovered |